BKS Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

BKS Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,000	Closed	-$242K	–	214
2017 Q1	$242K	Sell	2,000 -2,000	-50%	-$258K	0.11%	167
2016 Q4	$489K	Hold	4,000	–	–	0.23%	111
2016 Q3	$490K	Hold	4,000	–	–	0.23%	99
2016 Q2	$467K	Hold	4,000	–	–	0.24%	99
2016 Q1	$557K	Hold	4,000	–	–	0.29%	87
2015 Q4	$763K	Buy	+4,000	New	+$699K	0.39%	68
2015 Q3	–	Sell	-8,305	Closed	-$1.5M	–	164
2015 Q2	$1.5M	Hold	8,305	–	–	0.72%	45
2015 Q1	$1.44M	Buy	+8,305	New	+$1.5M	0.68%	45

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BKS Advisors's ALXN Position: Q2 2017 in Review

BKS Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 2,000 shares — an estimated $242K sold.

BKS Advisors first reported a position in ALXN in Q1 2015 and held it in 8 quarters. The position peaked at $1.5M in Q2 2015. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

BKS Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
BKS Advisors sold 2,000 Alexion Pharmaceuticals shares in Q2 2017, an estimated $242K.
BKS Advisors first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 8 quarters.
BKS Advisors's Alexion Pharmaceuticals position peaked at $1.5M in Q2 2015.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on BKS Advisors's 13F filing for Q2 2017, filed 8 Aug 2017.